A new treatment without chemotherapy for indolent clinical forms of mantle cell lymphoma
A new treatment without chemotherapy is effective in treating indolent clinical forms of mantle cell lymphoma.
A study led by researchers from the Hospital Clínic‑IDIBAPS shows that a new treatment without chemotherapy is effective in treating indolent clinical forms of mantle cell lymphoma. The combination of ibrutinib and rituximab produced complete responses in over 80% of patients and allowed most patients to discontinue treatment after two years, demonstrating a promising alternative to conventional immunochemotherapy.
The results suggest that a less toxic, frontline therapy using ibrutinib and rituximab can provide durable disease control and enable treatment cessation, potentially improving quality of life and reducing long‑term toxicity in this patient subgroup.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies
- Mantle Cell Lymphoma
- Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study